This project is part of the EDCTP3 programme supported by the European Union
This project is part of the EDCTP3 programme supported by the European Union
Annually, over 35 million pregnancies occur in areas of moderate to high malaria transmission, and over 7 million pregnancies are exposed to malaria in the first trimester.
However, first-trimester pregnancies are generally excluded from clinical trials, making newer, effective antimalarials unavailable during this critical time.
Annually
Over
In 2022
The SAFIRE consortium aims to close the existing data and treatment gaps for this group of patients through a Phase 3b adaptive platform trial conducted in highly malarious areas of Kenya, Mali, Burkina Faso, Uganda and the Democratic Republic of Congo.
SAFIRE will evaluate and generate robust evidence on the safety, tolerability and efficacy of registered antimalarials, which will be beneficial for areas where artemether-lumefantrine (AL) is not used, aligning with the World Health Organization’s strategy of deploying diverse first-line treatments to combat antimalarial resistance.
Findings, including those generated through qualitative research, will be integrated into policies and guidelines, ensuring pregnant women can access the best treatment choices for malaria in early pregnancy.
